Archive · 20 Aug 2026
Merck-Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk in Trial
Merck and Moderna tested a new shot for people with melanoma.
Melanoma is a type of cancer that can come back after treatment.
The companies said their combined treatment helped patients stay free of returning cancer for longer.
It also appeared to reduce the chance that the cancer would spread to faraway parts of the body.
This means the treatment met the main goal of the trial.
However, the companies have not shared all the numbers yet.
Researchers still need to see how large the benefit was.
They also need to learn whether the treatment helps patients live longer overall.
Merck and Moderna said their combination treatment met the trial’s primary goal.
The treatment improved recurrence-free survival among melanoma patients.
Patients receiving the combination remained free of returning melanoma for longer.
The combination also helped prevent melanoma from spreading to distant parts of the body.
The companies have not released the full results, including the benefit’s exact size or overall-survival data.
- Who
- Merck and Moderna, along with patients with melanoma.
- What
- A trial found that a Merck-Moderna combination treatment improved recurrence-free survival and helped prevent melanoma from spreading to distant parts of the body.
- Why
- The treatment was tested to reduce melanoma recurrence and prevent the cancer from spreading.
- Companies
- Merck and Moderna
- Condition
- Melanoma
- Primary trial goal
- Improving recurrence-free survival
- Reported benefit
- Patients remained free of returning melanoma for longer
- Additional finding
- The combination showed a benefit in preventing melanoma from spreading to distant parts of the body
- Unreleased information
- The exact magnitude of the benefit and overall survival data